Syncrosome will attend the 19th Annual Biotech in Europe Forum (Basel, 24th to 26th of October 2019)

The 19th Annual Biotech in Europe Forum is recognised as the leading international stage for those interested in investing and partnering in the biotech and life science industry. The #Sachs_BEF19 forum will be held for the sixth time in Basel to be close to the largest biopharma hub in Europe and the Congress Center provides meeting space capable of handling several thousand one-to-one meetings as well as significant exhibition space. The programme will feature a number of plenary panels/workshops covering BD & Licensing in the main therapeutic areas.

Emmanuelle Bettendorf, Account Manager in Syncrosome since 2009, will attend this international congress and will present the preclinical’s activities of Syncrosome to the 700 delegates coming from Biotech and Pharma environment.

A few words about Syncrosome: 

Syncrosome is an Efficacy Characterization CRO and we offer relevant disease models, cutting-edge techniques and a comprehensive background of physiopathology to assist drug discovery companies.

We have developped and validated so far more than 15 disease models, and our flexible and human-sized organization can design and operate tailored experimental protocols to give you appropriate answers.

Our main activities consit in :

  • Drug Efficacy Studiesin several therapeutic areas :
    • Central Nervous Sytem, 
    • Cardiovascular and Metabolic disease, 
    • Respiratory,
    • Gastroenterology.

Early bioavailibility and CNS-PKon rodents and non-rodents with a high competence in the study of the Blood Brain Barrier passage.